Advertisement

Heart and Vessels

, Volume 34, Issue 2, pp 218–226 | Cite as

Obesity paradox in the era of percutaneous coronary intervention with 2nd-generation drug-eluting stents: an analysis of a multicenter PCI registry

  • Daisuke Ueshima
  • Shunji Yoshikawa
  • Taro Sasaoka
  • Yu Hatano
  • Ken Kurihara
  • Yasuhiro Maejima
  • Mitsuaki Isobe
  • Takashi AshikagaEmail author
Original Article
  • 55 Downloads

Abstract

Being overweight has been identified as independent risk factors for coronary artery disease. However, overweight patients have been reported frequently to have better mortality outcomes, and there is little data showing they are at a disadvantage regarding secondary prevention of cardiovascular events. We analyzed the influence of being overweight (defined as body mass index > 25 kg/m2) on adverse events in patients who underwent everolimus-eluting stent (EES) implantation using a multicenter registry with a maximum follow-up of 3 years. Propensity score matching was done for adjusting baseline characteristics. We defined primary end points as major adverse cardiac and cerebrovascular events (MACCE: a composite of mortality from all causes, nonfatal myocardial infarction, and nonfatal stroke) and “MACCE excluding non-cardiac mortality”. Other adverse events were analyzed as key secondary end points. Out of 1918 patients, 450 pairs were obtained through propensity score matching. Overweight patients were superior to non-overweight patients regarding MACCE (event rates: 8.2 vs. 13.8% in overweight vs. non-overweight, respectively; log-rank p = 0.009) and “MACCE excluding non-cardiac mortality” (5.9 vs. 10.1%, p = 0.03). On secondary end points, not only did overweight patients have significantly fewer major bleeding events (2.2 vs. 4.8%, p = 0.02), but they also had smaller adverse event rates for almost all such events; the differences were not statistically significant. Overweight patients had better outcomes for MACCE, even on excluding non-cardiac mortalities. No result was supportive of an evident advantage to non-overweight EES-implanted patients in terms of secondary prevention of cardiovascular events.

Keywords

Percutaneous coronary intervention Overweight Obesity Drug-eluting stent Mortality Major adverse cardiac or cerebrovascular events 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

380_2018_1234_MOESM1_ESM.pdf (1.6 mb)
Supplementary material 1 (PDF 1672 kb)

References

  1. 1.
    Berrington de Gonzalez A, Hartge P, Cerhan JR, Flint AJ, Hannan L, MacInnis RJ, Moore SC, Tobias GS, Anton-Culver H, Freeman LB, Beeson WL, Clipp SL, English DR, Folsom AR, Freedman DM, Giles G, Hakansson N, Henderson KD, Hoffman-Bolton J, Hoppin JA, Koenig KL, Lee IM, Linet MS, Park Y, Pocobelli G, Schatzkin A, Sesso HD, Weiderpass E, Willcox BJ, Wolk A, Zeleniuch-Jacquotte A, Willett WC, Thun MJ (2010) Body-mass index and mortality among 1.46 million white adults. N Engl J Med 363:2211–2219CrossRefGoogle Scholar
  2. 2.
    Bogers RP, Bemelmans WJ, Hoogenveen RT, Boshuizen HC, Woodward M, Knekt P, van Dam RM, Hu FB, Visscher TL, Menotti A, Thorpe RJ Jr, Jamrozik K, Calling S, Strand BH, Shipley MJ, Investigators B-CC (2007) Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons. Arch Intern Med 167:1720–1728CrossRefGoogle Scholar
  3. 3.
    WHO Expert Consultation (2004) Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363:157–163CrossRefGoogle Scholar
  4. 4.
    Gruberg L, Weissman NJ, Waksman R, Fuchs S, Deible R, Pinnow EE, Ahmed LM, Kent KM, Pichard AD, Suddath WO, Satler LF, Lindsay J Jr (2002) The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox? J Am Coll Cardiol 39:578–584CrossRefGoogle Scholar
  5. 5.
    Uretsky S, Messerli FH, Bangalore S, Champion A, Cooper-Dehoff RM, Zhou Q, Pepine CJ (2007) Obesity paradox in patients with hypertension and coronary artery disease. Am J Med 120:863–870CrossRefGoogle Scholar
  6. 6.
    Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Woo MA, Tillisch JH (2001) The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol 38:789–795CrossRefGoogle Scholar
  7. 7.
    Romero-Corral A, Montori VM, Somers VK, Korinek J, Thomas RJ, Allison TG, Mookadam F, Lopez-Jimenez F (2006) Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet 368:666–678CrossRefGoogle Scholar
  8. 8.
    Lancefield T, Clark DJ, Andrianopoulos N, Brennan AL, Reid CM, Johns J, Freeman M, Charter K, Duffy SJ, Ajani AE, Proietto J, Farouque O, Registry MIG (2010) Is there an obesity paradox after percutaneous coronary intervention in the contemporary era? An analysis from a multicenter Australian registry. JACC Cardiovasc Interv 3:660–668CrossRefGoogle Scholar
  9. 9.
    Oreopoulos A, Padwal R, Norris CM, Mullen JC, Pretorius V, Kalantar-Zadeh K (2008) Effect of obesity on short- and long-term mortality postcoronary revascularization: a meta-analysis. Obesity (Silver Spring) 16:442–450CrossRefGoogle Scholar
  10. 10.
    Akin I, Tolg R, Hochadel M, Bergmann MW, Khattab AA, Schneider S, Senges J, Kuck KH, Richardt G, Nienaber CA, Group DDS (2012) No evidence of “obesity paradox” after treatment with drug-eluting stents in a routine clinical practice: results from the prospective multicenter German DES.DE (German Drug-Eluting Stent) Registry. JACC Cardiovasc Interv 5:162–169CrossRefGoogle Scholar
  11. 11.
    Bundhun PK, Li N, Chen MH (2015) Does an obesity paradox really exist after cardiovascular intervention? A systematic review and meta-analysis of randomized controlled trials and observational studies. Medicine (Baltimore) 94:e1910CrossRefGoogle Scholar
  12. 12.
    Pezzini A, Grassi M, Paciaroni M, Zini A, Silvestrelli G, Iacoviello L, Di Castelnuovo A, Del Zotto E, Caso V, Nichelli PF, Giossi A, Volonghi I, Simone AM, Lanari A, Costa P, Poli L, Pentore R, Falzone F, Gamba M, Morotti A, Ciccone A, Ritelli M, Guido D, Colombi M, De Gaetano G, Agnelli G, Padovani A, Multicentre Study on Cerebral Hemorrhage in Italy I (2013) Obesity and the risk of intracerebral hemorrhage: the multicenter study on cerebral hemorrhage in Italy. Stroke 44:1584–1589CrossRefGoogle Scholar
  13. 13.
    Konishi Y, Ashikaga T, Sasaoka T, Kurihara K, Yoshikawa S, Isobe M (2016) Comparison of outcomes after everolimus-eluting stent implantation in diabetic versus non-diabetic patients in the Tokyo-MD PCI study. J Cardiol 67:241–247CrossRefGoogle Scholar
  14. 14.
    Ueshima D, Ashikaga T, Yoshikawa S, Sasaoka T, Hatano Y, Kurihara K, Maejima Y, Isobe M (2017) Effect of over-2-year dual antiplatelet therapy on the rate of major adverse cardiac and cerebral events for everolimus-eluting stent implantation: the landmark analysis from Tokyo-MD PCI registry. J Cardiol 69:815–822CrossRefGoogle Scholar
  15. 15.
    Kurihara K, Ashikaga T, Sasaoka T, Yoshikawa S, Isobe M, Tokyo MDPCISI (2017) Incidence and predictors of early and late target lesion revascularization after everolimus-eluting stent implantation in unselected patients in Japan. Catheter Cardiovasc Interv 90:78–86CrossRefGoogle Scholar
  16. 16.
    D’Agostino RB Jr (1998) Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17:2265–2281CrossRefGoogle Scholar
  17. 17.
    Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458CrossRefGoogle Scholar
  18. 18.
    Klein S, Burke LE, Bray GA, Blair S, Allison DB, Pi-Sunyer X, Hong Y, Eckel RH, American Heart Association Council on Nutrition PA, Metabolism (2004) Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 110:2952–2967CrossRefGoogle Scholar
  19. 19.
    Task Force for D, Treatment of Non STSEACSoESoC, Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, Fox KA, Hasdai D, Ohman EM, Wallentin L, Wijns W (2007) Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 28:1598–1660CrossRefGoogle Scholar
  20. 20.
    Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, Fesmire FM, Ganiats TG, Jneid H, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar JP, Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Zidar JP, American College of Cardiology Foundation/American Heart Association Task Force on Practice G (2011) 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable Angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J Am Coll Cardiol 57:e215–e367CrossRefGoogle Scholar
  21. 21.
    Stokes A, Preston SH (2015) Smoking and reverse causation create an obesity paradox in cardiovascular disease. Obesity (Silver Spring) 23:2485–2490CrossRefGoogle Scholar
  22. 22.
    Preston SH, Stokes A (2014) Obesity paradox: conditioning on disease enhances biases in estimating the mortality risks of obesity. Epidemiology 25:454–461CrossRefGoogle Scholar
  23. 23.
    Harrington M, Gibson S, Cottrell RC (2009) A review and meta-analysis of the effect of weight loss on all-cause mortality risk. Nutr Res Rev 22:93–108CrossRefGoogle Scholar
  24. 24.
    Collaboration Prospective Studies, Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, Qizilbash N, Collins R, Peto R (2009) Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 373:1083–1096CrossRefGoogle Scholar
  25. 25.
    Byrne J, Spence MS, Fretz E, Mildenberger R, Chase A, Berry B, Pi D, Janssen C, Klinke P, Hilton D (2009) Body mass index, periprocedural bleeding, and outcome following percutaneous coronary intervention (from the British Columbia Cardiac Registry). Am J Cardiol 103:507–511CrossRefGoogle Scholar
  26. 26.
    Delhaye C, Wakabayashi K, Maluenda G, Belle L, Ben-Dor I, Gonzalez MA, Gaglia MA Jr, Torguson R, Xue Z, Suddath WO, Satler LF, Kent KM, Lindsay J, Pichard AD, Waksman R (2010) Body mass index and bleeding complications after percutaneous coronary intervention: does bivalirudin make a difference? Am Heart J 159:1139–1146CrossRefGoogle Scholar
  27. 27.
    Cushman M, Yanez D, Psaty BM, Fried LP, Heiss G, Lee M, Polak JF, Savage PJ, Tracy RP (1996) Association of fibrinogen and coagulation factors VII and VIII with cardiovascular risk factors in the elderly: the Cardiovascular Health Study. Cardiovascular Health Study Investigators. Am J Epidemiol 143:665–676CrossRefGoogle Scholar
  28. 28.
    Sibbing D, von Beckerath O, Schomig A, Kastrati A, von Beckerath N (2007) Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. Am J Cardiol 100:203–205CrossRefGoogle Scholar
  29. 29.
    Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Barrera Ramirez C, Sabate M, Fernandez C, Hernandez-Antolin R, Escaned J, Alfonso F, Macaya C (2004) Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? J Invasive Cardiol 16:169–174Google Scholar
  30. 30.
    Lin GM, Li YH, Yin WH, Wu YW, Chu PH, Wu CC, Hsu CH, Wen MS, Voon WC, Wang CC, Yeh SJ, Lin WS, Taiwan Society of Cardiology Heart Failure with Reduced Ejection Fraction registry i, committee (2016) The obesity-mortality paradox in patients with heart failure in taiwan and a collaborative meta-analysis for East Asian patients. Am J Cardiol 118:1011–1018CrossRefGoogle Scholar
  31. 31.
    Clark AL, Fonarow GC, Horwich TB (2015) Impact of cardiorespiratory fitness on the obesity paradox in patients with systolic heart failure. Am J Cardiol 115:209–213CrossRefGoogle Scholar
  32. 32.
    Zamora E, Lupon J, de Antonio M, Urrutia A, Coll R, Diez C, Altimir S, Bayes-Genis A (2013) The obesity paradox in heart failure: is etiology a key factor? Int J Cardiol 166:601–605CrossRefGoogle Scholar
  33. 33.
    Matsushita K, Harada K, Miyazaki T, Miyamoto T, Kohsaka S, Iida K, Tanimoto S, Yagawa M, Shiraishi Y, Yoshino H, Yamamoto T, Nagao K, Takayama M (2017) Effect of heart failure secondary to ischemic cardiomyopathy on body weight and blood pressure. Am J Cardiol 120:1589–1594CrossRefGoogle Scholar
  34. 34.
    Rubin R (2018) Postmenopausal women with a “normal” BMI might be overweight or even obese. JAMA 319:1185–1187CrossRefGoogle Scholar

Copyright information

© Springer Japan KK, part of Springer Nature 2018

Authors and Affiliations

  • Daisuke Ueshima
    • 1
  • Shunji Yoshikawa
    • 2
  • Taro Sasaoka
    • 1
  • Yu Hatano
    • 1
  • Ken Kurihara
    • 3
  • Yasuhiro Maejima
    • 1
  • Mitsuaki Isobe
    • 4
  • Takashi Ashikaga
    • 1
    Email author
  1. 1.Department of Cardiovascular MedicineTokyo Medical and Dental UniversityTokyoJapan
  2. 2.Department of CardiologyYamate Medical CenterTokyoJapan
  3. 3.Ome Municipal General HospitalOmeJapan
  4. 4.Sakakibara Memorial HospitalFuchuJapan

Personalised recommendations